In another study, although there was a significantly high prevalence of anti-TRIM21/Ro52 in ovarian cancer patients, the presence of this antibody was correlated with higher overall survival compared with the antibody-negative ovarian cancer population [61]. Here, TRIM21 is linked to ovarian carcinoma.